Hangzhou Sumgen Biotech Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING5
READOUTS ≤12 MONTHS5
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SG301 Injection NCT06508983 |
P3 | Recruiting | Relapsed/Refractory Multiple Myeloma | 360 | 2027-03-31 |
| SG301 Injection NCT07764627 |
P2 | Not yet recruiting | Antibody Mediated Rejection | 10 | 2027-03-31 |
| low dose group NCT07710248 |
P2 | Recruiting | Primary Immune Thrombocytopenia | 60 | 2027-05-17 |
| SG301 SC Injection NCT07447986 |
P2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 120 | 2027-09-30 |
| SG2918 NCT07454187 |
P1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 40 | 2027-09-30 |
| SG1827 NCT07774611 |
P1/2 | Recruiting | Advanced Solid Tumors | 180 | 2028-06-30 |